ABSTRACT: N-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-ethyl)-6-fluoronicotinamide ([ 18 F]FNEM), a novel prosthetic agent that is thiol-specific, was synthesized using a one-pot two-step strategy: (1) 18 F incorporation by a nucleophilic displacement of trimethylammonium substrate under mild conditions; (2) 
F is the most clinically relevant positron emitting radioisotope 1 because of its favorable nuclear decay properties (β + 0.635 MeV, 97% abundance, half-life 109.8 min). 18 F-labeled peptides have been more widely used for diagnostic imaging in cancer and other diseases due to their nonimmunogenic behavior, intrinsic pharmacokinetic properties, high affinity, and readily available solid-phase chemistry to allow tuning of these properties.
One consideration for the development of radiotracers is the ability to achieve selective radiolabeling. Peptides are challenging in this regard, as the most common labeling methods employ species that react at amines due to their facile reaction with activated carboxylic acid groups (N-succinimidyl-4-[ 18 F ]fluorobenzoate, [ 18 F ]SFB, for example) 2, 3 or with aldehydes. 4, 5 Peptides of sufficient length may have several amines all with slightly different reaction rates. Regioselective radiolabeling may be important to retain binding affinity and selectivity for a given peptide. The ability to easily modify peptides to reduce the number of reactive sites to one is an enticing property of peptides. Furthermore, labeling with [ 18 F ]SFB often requires large excess of peptide or protein to achieve reasonably high radiochemical yield, which compromises specific activity and/or requires HPLC purification strategies. 6, 7 On the basis of the above considerations, a more selective surrogate instead of amino reactive functional group is necessary. A free thiol group from a cysteine residue is able to meet these requirements and is extensively studied in radiolabeling of peptides. Peptides can be engineered to contain a free thiol group to allow specific labeling. Thiols react selectively with maleimides, 8−11 a-halogenketones, 12−15 and phosphorothionate agents 16, 17 under mild conditions. The selectivity of prosthetic groups toward free thiol can be exemplified by bovine serum albumin (BSA) conjugation. BSA is a protein with 55 free amino groups and 35 thiol groups, 34 of which form a disulfide bond and with just one free thiol group for site-specific conjugation (Cys 34 ). 18, 19 Selective labeling of Cys 34 with 19 Glucagon-like peptide-1 (GLP-1) is an important glucosedependent hormone released mainly from the small intestine during the ingestion of food. 21 Its receptor (GLP-1R) is a G protein-coupled receptor mainly expressed in the pancreatic islet cells. GLP-1R is highly expressed in insulinomas. 22 Detection of insulinomas can be difficult by CT, echography, or MRI, due to their relatively small size in the pancreas. Thus, GLP-1R provides a very promising target for receptor-targeted imaging and therapy of insulinomas. However, the native GLP-1 is very unstable in vivo and can be degraded by dipeptidylpeptidase-IV via cleavage of two N-terminal residues, with a half-life less than 2 min, which limits its biomedical application. 23 We have been interested in the development of a peptide based imaging agent for GLP-1R based on radiometal 24 or fluorine-18 25−27 labeling to overcome the limitations with promising results. However, radiometal labeled peptides are thought to metabolize to radiometal-chelated amino acids that are able to be trapped in the tubular lysosomes, thereby delivering high radiation doses to the kidneys with potential nephrotoxicity. 28 Our group developed a series of 18 F-radiolabeled prosthetic groups for the purpose of labeling cysteine-engineered GLP-1 analogues for tumor targeting with considerable success. Two thiol site-specific prosthetic groups containing maleimide units, 
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C h e m i s t r y . N , N , N -T r i m e t h y l -5 -( ( 2 , 3 , 5 , 6 -tetrafluorophenoxy)carbonyl)pyridin-2-aminium Chloride 1. Compound 1 was synthesized by modifying a literature method. 30 Briefly, to a solution of 6-chloronicotinic acid (4.4 g, 27.9 mmol) and 2,3,5,6-tetrafluorophenol (TFP) (4.8 g, 28.9 mmol) in dioxane (150 mL) was added N,N′-dicyclohexylcarbodiimide (DCC) (5.7 g, 27.6 mmol); the mixture was stirred overnight at room temperature. Dicyclohexylurea (DCU) was removed by filtration, and the filtrate was evaporated in vacuum. The residue was purified by silica gel flash chromatography using hexane/CH 2 Cl 2 (5/1, v/v) as the eluent to afford compound 1 as a white solid (7.2 g, 84% 30 Briefly, to a solution of compound 1 (1.0 g, 3.3 mmol) in dry THF (15 mL) was added 1 M trimethylamine solution in THF (9.0 mL). A white precipitate was found 10 min after the reaction started, which was allowed to proceed overnight. The precipitate was collected and washed with cold Et 2 O and cold CH 2 Cl 2 successively. The solid residue was suspended in CH 2 Cl 2 , and TMSOTf (1.7 mL, 9 mmol) was added over 10 min. The mixture was concentrated, and the residue was recrystallized from EtOAc to afford compound 3 as a white solid (0.9 g, 57% yield). 1 for 0.5 h and continued at room temperature overnight. After confirmation from TLC that the starting material was consumed completely, the mixture was quenched with ice water and extracted with CH 2 Cl 2 . The organic extracts were washed with water and brine, respectively, then dried and the solvent rotary evaporated. The residue was purified by silica gel column chromatography with CH 2 Cl 2 /MeOH as the eluent to afford the amide compound.
N-(2-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-6-fluoronicotinamide 5 (FNEM). Compound 5 was prepared according to the general procedure as a white solid (83 mg, yield 79%). 1-Hexyl-1H-pyrrole-2,5-dione 8. Hexylamine (50 mg, 0.5 mmol) was dissolved in a saturated aqueous solution of NaHCO 3 (2 mL). The solution was put on ice-bath, and after 5 min, N-(methoxycarbonyl)maleimide (93 mg, 0.6 mmol) was added. The resulting solution was stirred on ice-bath for 30 min and then at room temperature for an additional 30 min until all the starting material was consumed completely as confirmed by TLC. The mixture was purified through silica gel flash chromatography using CH 2 Cl 2 /MeOH as the eluent to afford compound 8 as a colorless liquid (68 mg, yield 76%). ]-exendin-4 in degassed PBS, FNEM or Nhexylmaleimide in acetonitrile was added and incubated for 1 h; then the mixture was subjected to semipreparative HPLC (Vydac C 18 protein column, 9.4 × 250 mm, flow rate 5.0 mL/ min, solvent A, 0.1% TFA in water, solvent B, 0.1% TFA in CH 3 CN). The elution profile was isocratic at 25% solvent B for 5 min, then a gradient to 55% solvent B over 25 min, and finally to 90% B over the next 5 min) 27 . The fluoride was dried by adding acetonitrile (200 μL) three times and each evaporated. Then triflate 9 (9 mg, 18.8 μmol) in acetonitrile/ t BuOH (300 μL/100 μL) was added. The reaction mixture was heated at 40°C for 10 min, cooled to room temperature, and then N-(2-aminoethyl)maleimide trifluoroacetate salt (12 mg, 47.2 μmol) and pyridine (7.6 μL) in acetonitrile (170 μL) was added to the mixture. The reaction solution was further heated at 60°C for 15 min. The solvent was evaporated by argon flow and diluted with 1 mL of 10% aqueous CH 3 CN; the mixture was centrifuged and subjected to semipreparative HPLC purification with Phenomenex Luna 5 μm C 18 column (250 × 10 mm, flow rate 4.0 mL/ min). The collected fraction was diluted with 10 mL of water, and the product was trapped on two stacked Sep-Pak C 18 plus cartridges. The cartridge was washed with H 2 O (3 mL) and hexane (2 mL) successively, and the product was eluted with 10% EtOH in CH 2 Cl 2 (1.5 mL). The solvent was removed under argon flow. A typical one-pot two-step radiolabeling would require 75 min. The purity of compound 5 was confirmed by analytical HPLC (Phenomenex Luna 3 μm C 18 column, 150 × 4.6 mm, flow rate 1.0 mL/min, isocratic elution with 15% CH 3 ]-exendin-4 (100−200 μg) in 100 μL 0.1% sodium ascorbate in degassed PBS was added, and the reaction mixture was incubated at room temperature for 30 min. Then to the mixture was added N-hexylmaleimide 8 (160 μg) in acetonitrile (150 μL), and the reaction stood for another 20 min. Then 0.1% TFA (100 μL) was added, and the mixture was subjected to semipreparative HPLC purification. The collected fractions were diluted with water and passed through a C 18 BondElut cartridge. The product was eluted with 1.5 mL of 10 mM HCl in ethanol, and the volume was reduced to about 100−200 μL on a rotary evaporator. 40 ]-exendin-4 in serum, the radiotracer (142 μCi) was mixed with freshly harvested mouse serum (200 μL).
A 50 μL aliquot was removed at 0 min, and the remaining sample was incubated at 37°C. Additional aliquots of 50 μL were removed at 30, 60, and 90 min. Each aliquot was mixed with 50 μL of CH 3 CN and centrifuged. A portion of the supernatant was taken for radioHPLC analysis using an online radioactivity detector.
Cell Cell Experiments. The GLP-1R binding assay was performed according to a reported procedure 27 40 ]-exendin-4 were also conducted as previously reported. 27 PET Imaging. When the INS-1 tumor reached 8−10 mm in size (18−24 days after inoculation), PET imaging studies were performed using an Inveon small animal PET scanner (Siemens Preclinical Solutions). Tumor mice were randomly divided into the control group and the blocking group (n = 5/group). For the control group, about 1. 40 -exendin-4. For both groups, a 5 min acquisition was performed at 1 and 2 h after tracer injection. The images were reconstructed using a 2D OSEM algorithm without correction for attenuation or scattering. The mean pixel values within the three-dimensional regions of interest (3D-ROIs) were converted to MBq/mL/ min using a predetermined calibration factor. By assuming a tissue density of 1 g/mL, imaging ROI-derived % ID/g was obtained.
Ex Vivo Biodistribution. Immediately after the 2 h microPET imaging, tumor model mice in both groups were sacrificed, and INS-1 tumor, blood, major organs, or tissues were harvested and wet weighed. The radioactivity of each organ or tissue was measured using a γ-counter, and the results were expressed as percentages of the injected dose per gram of tissue (%ID/g).
Statistical Analysis. Quantitative data were expressed as mean ± SD, and the results were compared using Student's t test. P value of <0.05 is considered statistically significant.
■ RESULTS
Chemistry and Radiochemistry. Following literature procedures, 30 we first synthesized compound 1 from 6-chloronicotinic acid and 2,3,5,6-tetrafluorophenol by N,N′-dicyclohexylcarbodiimide condensation. With slight modification of the literature procedure, we found that chloride 2 was obtained in good yield using 1 M trimethylamine solution in THF instead of using trimethylamine gas. The chloride salt 2 with poor solubility in acetonitrile was converted to the trifluoromethanesulfonate salt by adding trimethylsilyl trifluoromethanesulfonate (TMSOTf) to a suspension of 2 in dichloromethane. Purified needle-shaped 3 was conveniently produced by recrystallization of the concentrated organic phase from ethyl acetate. This triflate salt 3 had excellent solubility in the commonly used radiolabeling solvent acetonitrile (Scheme 1).
Next we evaluated radiolabeling of the triflate salt 3. The radiolabeling proceeded well when using the optimized conditions developed by Olberg. 30 Olberg used an Oasis MCX Plus Sep-Pak (Waters) to purify the resulting radiolabeled product 4, eliminating the time-consuming HPLC purification step. However, in the subsequent peptide conjugation, 2 mg of peptide in 3 mL of buffer was required. It was our observation, that the product 4, purified by solidphase extraction, contained a significant amount of 2,3,5,6-tetrafluorophenyl 6-(2,3,5,6-tetrafluorophenoxy)nicotinate, resulting from 2,3,5,6-tetrafluorophenol substitution of the trimethylammonium leaving group. Indeed we found that 3 efficiently reacted with 2,3,5,6-tetrafluorophenol in the presence of base to provide 95% isolated yield of the side product. Although the incorporation of [ 18 F] fluoride was very good, we observed HPLC purification to be adversely affected by the t BuOH in the reaction (see discussion below). Subsequently, we found that with smaller volume (0.4 mL instead of 1 mL) of solvent and changing the t BuOH/MeCN ratio from 4/1 to 1/3 still gave 67−82% radiochemical yields.
Next we focused on maleimide incorporation without requiring a solvent change. We evaluated the amount of N-(2-aminoethyl)maleimide and different bases to achieve the desired coupling. Base with higher pK a typically gave lower yield or completely degraded polar stuff (Table 1, entry 1, 9) ; diisopropylethylamine proved to be an appropriate base for the coupling while higher temperature with excess amount of the base afforded no product (Table 1 , compare entry 2, 3). We also unsuccessfully tried the coupling in aqueous buffer, which gave very low yield (Table 1 , entry 4). Finally, we found pyridine (pK a 5.25) formed a stable solution with N-(2-aminoethyl)maleimide and afforded good yield for the condensation; further increasing the amount of maleimide and elevating the reaction temperature gave improved results (Table 1 , entry 5−8). The desired product was verified by coinjection of authentic FNEM, which was prepared by the condensation of 6-fluoronicotinic acid and N-(2-aminoethyl)-maleimide. The radiotracer was further confirmed by LC−MS.
We knew we needed to remove the side product (product 3 + tetrafluorophenol). First we tried fluorous cartridge to separate the two components based on the fluorophilicity interaction instead of eluent polarity but were unsuccessful. We returned our focus to HPLC purification because we had good analytical conditions. At the end of the reaction, we diluted the reaction solution to 0.4, 1, or 4 mL and injected onto a semipreperative column. Our initial semipreparative conditions (isocratic with 0.1% TFA in 15% water, 85% acetonitrile) for HPLC resulted in a product peak with a 4 min peak width (baseline to baseline) at 18 min. The amount of aqueous dilution of the reaction mixture (up to 0.6, 1, or 4 mL with water) did not improve the peak shape. Even on an analytical system, optimal peak shape was not obtained unless the tertbutanol was completely evaporated. Because of the large volume of collected fraction from the semipreparative column, we were unable to trap the desired product on a solid phase extraction column.
Attempts to modulate the peak width using more basic HPLC eluents, such as ammonium acetate buffer (50 mM, pH 6.4) or PBS buffer (pH 7.2), provided no improvement in peak shape. The retention time of [ 18 F]FNEM was around 8.9 min with 15% isocratic acetonitrile for analytical HPLC in all tested buffers (0.1% TFA, pH 6.4, pH 7.4). We hypothesized that the tert-butanol in the reaction solvent was causing the unfavorable peak shape. Evaporation of the reaction solvent prior to HPLC injection provided better resolution. Typically the tracer was collected in 26 ± 5% (n = 8) uncorrected yield from EOB, and the total radiochemical synthesis time was around 75 min with specific activity 19−88 GBq/μmol (n = 8). Moreover, the trapping efficiency from the HPLC eluate was around 70% when the HPLC fraction (approximately 6 mL) was diluted to 21 mL with pure water. Up to 90% of the activity was trapped when a stack of two Waters C 18 plus cartridges was used. Following washes with H 2 O and hexane, the tracer was efficiently eluted (80 ± 5% recovery) with 10% ethanol in dichloromethane.
In order to demonstrate the application of this novel nicotinic maleimide prosthetic group, we applied the methods previously used for [ 18 Our next approach to achieve higher chemical purity was to consume excess [Cys 40 ]-exendin-4 with a much more lipophilic maleimide that could be added following reaction time with [ 18 F]FNEM. Two lipophilic maleimide prosthetic agents 6 and 7 were prepared through condensation of 3,3,3-triphenylpropionic acid and 2-naphthoic acid with N-(2-aminoethyl)-maleimide), respectively (Scheme 2). After the radiolabeling reaction, we added 10 equiv of 6 or 7 in acetonitrile to consume excess free thiol compound, but the trial failed probably due to the high hydrophobicity of 6 and 7 that precludes dispersion into aqueous phase. Inspired by our previous work, we synthesized another maleimide prosthetic agent 8 with a hexyl chain, which would have similar lipophilicity to fluoropentyl group and may capture 40 ]-exendin-4 was studied at 37°C in mouse serum and was shown to be stable up to 90 min. Trace amount of a polar component was produced, which may be due to oxidation of methionine group on the peptide (Figure 1) . 31, 32 The tracer is stable enough to acquire appropriate PET imaging results. The extraction efficiency from the mouse serum was around 80%, as determined by the ratio of radioactivity in the supernatant compared to the pellet.
Cell (Figure 3) . Uptake was apparent (0.34 ± 0.04%) at 15 min, and there was sustained increase until 60 min (0.63 ± 0.08%), then the uptake decreased at 2 h (0.38 ± 0.02%). The uptake was effectively inhibited in the presence of a blocking dose of exendin-4. The efflux appeared to be biphasic with an early rapid washout, reflecting the loss of surface receptor binding, followed by a slow loss of radioactivity from the cells, representing the clearance of internalized radioactivity, about 42% of the activity effluxed from the cells by 60 min.
PET Imaging and ex Vivo Biodistribution. The PET images clearly showed high uptake of [ 18 PET imaging results at 2 h post-tracer injection. In the control group, INS-1 tumor uptake was 23.06 ± 3.87 %ID/g, while in blocking group the tumor showed only 0.35 ± 0.23 %ID/g (P < 0.01). Tumor-to-kidney ratio was 11, and tumor-to-liver ratio was 63.8 ( Figure 4 ). The blocking dose led to reduced uptake in the GLP-1R positive organs such as pancreas, stomach, and lung.
■ DISCUSSION Direct radiolabeling of peptides/proteins usually requires high temperature and strong basic medium, with which most peptides are incompatible. 33−39 Labeling strategies for the introduction of 18 F into peptides or proteins most often utilize radiolabeled prosthetic groups. 40−43 The small 18 F-labeled prosthetic groups often require multiple synthetic steps to construct before final conjugation to the ligand of interest under mild conditions. 44 Several factors are essential to the successful application of 18 F-labeled prosthetic groups: speed of synthesis, selectivity of reactivity, and specific activity.
The speed of a radiochemical synthesis is an important factor in the utility and translation of any radiotracer employing a short-lived radionuclide. The application of rapid synthetic reactions and solid-phase extraction methods, instead of HPLC, generally reduce preparation time at the potential expense of lower purity. In the case of 18 F, the development of labeling procedures that can be conducted in aqueous media avoids the time required to render fluoride anhydrous for traditional labeling methods. These methods include the use of silicon 33,45−47 or boron 48−51 based fluorine acceptor groups for 18 F incorporation, oxime formation under aqueous conditions by conjugation of [ 18 58 reported the radiolabeling of fluorous-tagged precursors by nucleophilic fluorination and subsequent purification by fluorous solid phase extraction based on the different affinities of the unreacted substrate and the radiolabeled product for the stationary phase.
High specific activity of the final radiolabeled peptide is often desirable since the receptors or enzymes, recognized by the peptides, would be competitively bound with nonradioactive ligands. Sufficiently low concentration (<0.1 × K d ) of the tracer bound to the target is usually required to avoid pharmacological effects for regulatory approval. 59 With our ongoing interest in the development of efficient radiolabeling strategies, we developed three thiol site-specific 18 F-radiolabeling prosthetic groups recently. The efficiency in terms of radiochemical yield, preparation time, and specific activity was outlined in Table 2 . The newly developed [ 18 F ]FNEM was achieved with higher yield in shorter time using a one-pot two-step strategy compared to our previously described [ 18 26 which employ a three-step synthesis and two reaction vessels. We attempted to obtain a 18 F radiolabeled maleimide prosthetic group using one-step radiolabeling method that was unsuccessful, due to the lability of maleimide group under harsh conditions. All three thiol-site specific groups showed high specific activity and good radiochemical purity ( Table 2) .
The conjugation with [Cys 40 ]-exendin-4 using the developed thiol site-specific prosthetic agents proceeded smoothly with 30−40% decay uncorrected yield. The images for insulinoma targeting showed similar results for [ 18 ]-exendin-4 version. There is a literature report that replacement of a phenyl group with a pyridine moiety will affect the binding affinities of somatostatin receptors in terms of electrostatic potentials through tuning the water solubility and hydrogen bonding capacity, apparently it would change the pK a and configuration after modification. ]-exendin-4, previously developed by our group, and shows high tumor-to-normal tissue ratios for insulinoma imaging. The tracer has rapid renal clearance and low accumulation in the liver.
[ 18 F ]FNEM may be used to site-specifically radiolabel thiol-containing proteins, antibodies, aptamers, and oligonucleotides. 
